You are here

  • Home
  • Archive
  • Volume 21, Issue 5
  • Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta analysis
Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes
  1. David W Johnson
  1. University of Queensland, Brisbane, Queensland, Australia
  1. Correspondence to: Department of Nephrology, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia; david.johnson2{at}health.qld.gov.au

https://doi.org/10.1136/ebmed-2016-110418

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev 2016;(1):CD003266

    Context

    Anaemia frequency and severity worsen with advancing chronic kidney disease (CKD) and are associated with quality-of-life (QOL) impairment, morbidity and mortality.1 Deficient renal erythropoietin production is a major cause and can be corrected by recombinant human erythropoietin (rhEPO) administration.1 This may improve clinical outcomes, including delaying dialysis. Conversely, rhEPO therapy causes hypertension,2 thereby potentially accelerating CKD progression. This systematic review and meta-analysis examined rhEPO effects on clinical outcomes in anaemic, pre-dialysis CKD patients.

    Methods

    Randomised controlled trials (RCTs) comparing rhEPO treatment with either placebo …

    View Full Text

    Footnotes

    • Competing interests DWJ has previously received consultancy fees, research grants, speaker's honoraria and travel sponsorships from Amgen, Roche and Janssen-Cilag.

    • Provenance and peer review Commissioned; internally peer reviewed.